Rusfertide is a first-in-class hepcidin mimetic indicated for erythrocytosis in adults with polycythemia vera, acting through ferroportin blockade to limit iron availability for red blood cell production. It is a synthetic cyclic peptide that blocks the iron transporter ferroportin, reducing the availability of iron for red blood cell production and lowering hematocrit.
- Mechanism
- Curator reviewed · 2 references
Rusfertide is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin. Inhibition of ferroportin by rusfertide reduces the availability of iron for production of red blood cells, resulting in lower hematocrit levels.
- Primary indication
- Rusfertide is indicated for the treatment of erythrocytosis in adults with polycythemia vera.Curator reviewed · 1 structured indication
- Also known as
- Isovaleryl-asp-thr-his-phe-pro-cyclo(cys-ile-lys(palm-gamma-glu)- phe-glu-pro-arg-ser-lys-gly-cys)-lys-nh2
- Code names
- PTG-300 · PTG-300FB
Resolves to
What you can answer from here — as of September 11, 2026
Which drugs share a target with Rusfertide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account